SB-242235 is a potent and selective p38 MAP kinase inhibitor used to inhibit p38 activity and downstream MAPKAPK-2 activation in human chondrocytes; it suppresses the expression of pro-inflammatory cytokines (e.g., IL-6, KC/murine IL-8) and COX-2; it also abolishes MAPKAPK-2 activity and HSP27 phosphorylation in vivo, demonstrating anti-inflammatory effects in models of UVB-induced skin inflammation.